Amplifold develops the next generation of rapid tests using DNA origami nanotechnology – tiny structures made from DNA that we design to detect specific molecules with extremely high accuracy.
Amplifold has raised €5.0M across 1 funding round from 5 investors, most recently a Seed round in Dec 2025. Based in Munich, Germany; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-12-10 | Seed | €5.0M |
| b2venture ,Bayern Kapital,Becker Ventures,Matterwave Ventures,xista science ventures |
| View deal → |
